Lacutoclax

乐托克拉

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameLacutoclax
Drug Alias NameLP-108
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApoptosis regulator Bcl-2 inhibitors
TargetsApoptosis regulator Bcl-2
Therapy Area/IndicationsMyelodysplastic SyndromesLymphoma, B-CellLymphoma, Non-Hodgkin +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomSpain +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGuangzhou Lupeng Pharmaceutical Co LtdNewave Pharmaceutical Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesNewave Pharmaceutical IncGuangzhou Lupeng Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLymphoma, B-CellLymphoma, Non-Hodgkin +[10] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A